Gault Cheryl 4

What Happened
Cheryl Gault, Chief Operating Officer of Rapport Therapeutics (RAPP), sold 2,014 shares of common stock on March 5, 2026. The reported weighted‑average price was $28.93 per share, for proceeds of approximately $58,265. This was a sale (not a purchase) and is described in the filing as a tax‑withholding transaction related to the vesting of restricted stock units, not a discretionary trade.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (filed within the required 2 business days).
• Shares sold: 2,014; weighted average price reported: $28.93; proceeds ≈ $58,265.
• Price range: shares were sold in multiple transactions at prices from $28.34 to $28.94 (weighted average shown).
• Footnote: Sale made to satisfy taxes associated with RSU vesting (i.e., tax withholding), so not a discretionary sale. More granular per‑trade detail can be provided to the SEC on request.
• Shares owned after transaction: not specified in the supplied summary.

Context
Tax‑withholding sales following RSU vesting are routine and are generally used to cover tax obligations rather than to express an investment view. Such transactions should be interpreted as administrative rather than a direct signal of insider sentiment.